November 21, 2025

The technological trajectory of spinal minimally invasive surgery (MIS) and interventional techniques is globally trending toward increased precision, intelligence, reduced invasiveness, and advanced biological solutions. In this context, China’s medical device enterprises have transitioned from early technology adopters to significant innovation drivers across several sub-segments, notably in interventional surgical instruments and procedural advancement.

This evolution is compelling for international stakeholders as Chinese firms develop products that meet both domestic needs and international standards.

---

1. The Emerging Domestic Innovation Landscape

The push for innovation in China has led to the development of domestically competitive enterprises and products. The current focus is on building complete product systems that support advanced surgical techniques, driven by unmet clinical needs.

1.1 Surgical Robotics

TINAVI – TiRobot Orthopedic Surgical Robot: This system utilizes intraoperative 3D imaging and mechanical arm guidance. It employs intelligent algorithms to calculate implant trajectories and enables the robotic arm to move to the planned position with sub-millimeter accuracy, providing a stable pathway for guide wire and implant placement.

Futurtec – ORTHBOT® Spinal Surgical Robot: This device is noted as the first domestic robot capable of automatically executing the needle placement operation, providing full-process automation. The system incorporates a pressure-sensing mechanism for real-time monitoring and safety, alongside proprietary visible light navigation to mitigate potential interference.

1.2 Spinal Endoscopy Systems

Cansun – Foraminoscopy System: Offering channel diameters of 3.7MM and 4.7MM with dual water channels, this system utilizes a sapphire scratch-resistant lens. The compact optical structure is designed to deliver high resolution, excellent color reproduction, and optimal depth of field.

1.3 Vertebroplasty and Stabilization

Wego – Vertebroplasty/Kyphoplasty Kit: As a leading domestic orthopedic manufacturer, its products, including balloons and bone cement, are recognized for their stable quality. The company holds a significant share in the Chinese market, having largely achieved large-scale import substitution in this segment.

Kinetic – Compliance Vertebral Expansion Balloon Catheter System: Kinetic holds a significant market position in China, offering systems for both Percutaneous Vertebroplasty (PVP) and Percutaneous Kyphoplasty (PKP).

Sanyou – MIS Spinal Internal Fixation System: This system is applicable to both traditional open surgery and MIS percutaneous internal fixation for the thoracolumbar spine.

---

2. Domestic Development Trajectory and International Intent

Chinese enterprises often apply a “clinical needs-driven” and “differentiated innovation” strategy to catch up with internal competitions. This approach allows for a rapid market response, quickly providing full sets of instruments that accelerate the adoption of new surgical techniques nationwide. This rapid development has led to an industry pattern characterized as “Intermediate Strength, Catching Up at Both Ends”:

Strength in the Middle: Chinese companies have achieved import substitution and hold a dominant position in midstream, technology-mature products that rely on precision manufacturing, such as endoscopes and percutaneous screws. In surgical robotics, they have achieved technological parity or even leadership.

Catching Up at the Ends: The upstream (e.g., specific advanced imaging components for robotics) still demonstrates reliance on imports. Simultaneously, the downstream (e.g., innovation in advanced biological materials) is an area where domestic R&D is being significantly intensified.

Companies like Futurtec reflect the international ambitions of the sector. After extensive clinical validation within China, the company is actively pursuing international regulatory approvals for its Orthbot robot to facilitate its entry into the international market and build an integrated “equipment + consumables” global ecosystem.

---

3. Strategic Implications for International Stakeholders

The sustained momentum of China’s spinal medtech sector creates specific strategic considerations for global entities, affecting both entry strategy into China and partnership development.

3.1 Outbound Opportunity: Global Distribution and Sourcing

The successful acquisition of international regulatory approvals validates the quality and safety of these devices. This provides global distributors with an opportunity to source sophisticated, certified spinal devices and introduce a competitive value proposition to their respective markets.

3.2 Inbound Opportunity: Technology Partnership and Market Access in China

The Chinese market remains critical due to its size and growth, but it is increasingly complex for imported products. Foreign manufacturers with competitive devices must adapt to government policies aimed at import substitution and controlling costs.

Strategic Imperatives for Foreign Manufacturers in China:

• Localization of Production: To mitigate the impact of Volume-Based Procurement (VBP), which drastically lowers prices for high-volume products, foreign companies are incentivized to establish local manufacturing or “In-China-for-China” operations. This often allows products to be classified as domestic, improving eligibility for VBP tenders and potentially benefiting from streamlined regulatory pathways for local production transfers.
• Focus on Differentiation: As commoditized segments (like basic implants) face VBP pressure, foreign firms must shift focus to high-value, highly innovative segments such as advanced robotics, specialized MIS implants, and motion-preserving technologies where domestic competition is still developing. This requires justifying a premium price through superior clinical evidence, dedicated training, and service support.
• Strategic Partnerships: Collaborating with established domestic players through joint ventures or licensing can mitigate regulatory hurdles, provide immediate access to broad hospital networks, and help navigate the complex, rapidly evolving local procurement ecosystem.
• Portfolio Management: Foreign companies should accelerate the commercialization of new, innovative pipeline products that are not yet subject to VBP, while optimizing the cost structure and commercial models for their legacy portfolios.

3.3 Investment in Innovation

Targeting firms actively seeking international certification or those dominating domestic segments allows investors to participate in the accelerated global commercialization of differentiated, clinically validated technologies. Furthermore, targeting the upstream supply chain reliance presents an opportunity for international component manufacturers and technology firms to secure a favorable market position in China by supporting domestic champions in their quest for vertical integration.

In summary, the trajectory of China’s spinal medtech industry warrants the careful attention of global stakeholders. The sector is evolving rapidly, generating highly capable, internationally certified devices and simultaneously revealing specific areas where mutual technology and market cooperation could yield significant, synchronized growth.

By Andy WANG & Vivian LIU

---

Disclaimer: This report is for general informational and analytical purposes only, based on publicly available data and our own proprietary synthesis and analysis. While we strive for accuracy, the information and our interpretations may differ from the original sources. This content is not a substitute for professional counsel, due diligence, or primary source consultation. We assume no liability for actions taken based on the information provided herein.